Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LXEO 
Lexeo Therapeutics, Inc. Common Stock (LXEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: LXEO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.38
1 Year Target Price $16.38
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.94% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 279.73M USD | Price to earnings Ratio - | 1Y Target Price 16.38 |
Price to earnings Ratio - | 1Y Target Price 16.38 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.45 - 11.30 | Updated Date 09/15/2025 |
52 Weeks Range 1.45 - 11.30 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.91% | Return on Equity (TTM) -75.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 155746288 | Price to Sales(TTM) - |
Enterprise Value 155746288 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 416.34 | Enterprise Value to EBITDA -6.02 | Shares Outstanding 54001200 | Shares Floating 29378358 |
Shares Outstanding 54001200 | Shares Floating 29378358 | ||
Percent Insiders 0.53 | Percent Institutions 89.37 |
Upturn AI SWOT
Lexeo Therapeutics, Inc. Common Stock
Company Overview
History and Background
Lexeo Therapeutics is a clinical-stage gene therapy company focused on developing treatments for genetic diseases. Founded in 2019, it has rapidly advanced its pipeline through preclinical and clinical development, focusing on diseases with significant unmet needs.
Core Business Areas
- Gene Therapy Development: Lexeo focuses on developing adeno-associated virus (AAV)-based gene therapies for genetic diseases. Their therapies are designed to deliver functional genes to cells, addressing the underlying cause of the disease.
- Neurological Diseases: The company's primary focus is on neurological diseases, particularly those affecting the central nervous system.
Leadership and Structure
The leadership team includes experienced executives in gene therapy and drug development. The organizational structure is typical of a clinical-stage biotech company, with functional teams for research, development, clinical operations, and regulatory affairs. Rachel McMinn, PhD is the CEO. The company operates with a focus on agility and speed to market.
Top Products and Market Share
Key Offerings
- LX1001: LX1001 is an AAV-based gene therapy candidate for CLN2 disease (Batten disease), a rare and fatal neurodegenerative disorder. It is currently in clinical trials. Market share is N/A as it is not yet approved. Key competitors include BioMarin Pharmaceutical (BMNM) which has approved treatment for some forms of Batten Disease.
- LX2006: LX2006 is an AAV gene therapy for Friedreichu2019s Ataxia, currently in clinical trials. Market share is N/A as it is not yet approved. There are currently no approved therapies for Friedreich's Ataxia, so the competitive landscape is focused on companies developing novel treatments.
Market Dynamics
Industry Overview
The gene therapy market is experiencing rapid growth, driven by technological advancements and increasing regulatory support. It is characterized by high research and development costs, regulatory hurdles, and the potential for high returns.
Positioning
Lexeo Therapeutics is positioned as a clinical-stage company with a promising pipeline targeting neurological diseases. Their competitive advantage lies in their experienced team, focus on unmet needs, and AAV gene therapy platform.
Total Addressable Market (TAM)
The TAM for gene therapies addressing neurological disorders is estimated to be in the billions of dollars. Lexeo is positioned to capture a significant portion of this market with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on unmet medical needs
- Strong AAV gene therapy platform
- Promising clinical trial results
- Novel therapeutic approach
Weaknesses
- Dependence on clinical trial success
- Limited commercial infrastructure
- High cash burn rate
- Early stage company
Opportunities
- Positive clinical trial outcomes
- Regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other gene therapy companies
- Manufacturing challenges
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- BMNM
- CRIS
- SRPT
Competitive Landscape
Lexeo faces competition from established pharmaceutical companies and other gene therapy developers. Its advantages lie in its focus on neurological diseases and promising AAV gene therapy platform. Disadvantages include its smaller size and limited commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Lexeo's historical growth is characterized by its rapid advancement of its pipeline from preclinical to clinical stages.
Future Projections: Future growth is projected to be driven by positive clinical trial data, regulatory approvals, and potential partnerships. Analyst estimates vary depending on the success of their lead programs.
Recent Initiatives: Recent initiatives include advancing its lead programs (LX1001 and LX2006) through clinical trials, expanding its pipeline with new gene therapy candidates, and securing partnerships for manufacturing and commercialization.
Summary
Lexeo Therapeutics is a promising clinical-stage gene therapy company with a focus on neurological diseases. The company has a strong pipeline, an experienced management team, and a novel therapeutic approach. Its success depends heavily on positive clinical trial outcomes and regulatory approvals. However, it needs to be aware of the financial costs for research and development and the ability to manage its cash flow so that it is able to bring its key products to market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Investor Presentations, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexeo Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2023-11-03 | CEO & Director Mr. R. Nolan Townsend | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.lexeotx.com |
Full time employees 61 | Website https://www.lexeotx.com | ||
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.